USA - NASDAQ:ROIV - BMG762791017 - Common Stock
The current stock price of ROIV is 16.04 USD. In the past month the price increased by 13.92%. In the past year, price increased by 34.79%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.77 | 407.19B | ||
AMGN | AMGEN INC | 13.3 | 156.19B | ||
GILD | GILEAD SCIENCES INC | 15.14 | 145.40B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.07 | 104.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.36B | ||
REGN | REGENERON PHARMACEUTICALS | 12.37 | 59.85B | ||
ARGX | ARGENX SE - ADR | 85.97 | 48.77B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.17 | 35.16B | ||
INSM | INSMED INC | N/A | 34.31B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
NTRA | NATERA INC | N/A | 23.23B | ||
BIIB | BIOGEN INC | 9.15 | 21.49B |
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
ROIVANT SCIENCES LTD
7Th Floor, 50 Broadway
London GB
Employees: 750
Phone: 4412955950
The current stock price of ROIV is 16.04 USD. The price decreased by -0.5% in the last trading session.
The exchange symbol of ROIVANT SCIENCES LTD is ROIV and it is listed on the Nasdaq exchange.
ROIV stock is listed on the Nasdaq exchange.
18 analysts have analysed ROIV and the average price target is 20.04 USD. This implies a price increase of 24.96% is expected in the next year compared to the current price of 16.04. Check the ROIVANT SCIENCES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ROIVANT SCIENCES LTD (ROIV) has a market capitalization of 10.95B USD. This makes ROIV a Large Cap stock.
ROIVANT SCIENCES LTD (ROIV) currently has 750 employees.
ROIVANT SCIENCES LTD (ROIV) has a support level at 16.03 and a resistance level at 16.17. Check the full technical report for a detailed analysis of ROIV support and resistance levels.
The Revenue of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -75.92% in the next year. Check the estimates tab for more information on the ROIV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ROIV does not pay a dividend.
ROIVANT SCIENCES LTD (ROIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
The outstanding short interest for ROIVANT SCIENCES LTD (ROIV) is 8.5% of its float. Check the ownership tab for more information on the ROIV short interest.
ChartMill assigns a technical rating of 9 / 10 to ROIV. When comparing the yearly performance of all stocks, ROIV is one of the better performing stocks in the market, outperforming 89.44% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ROIV. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ROIV reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 9.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -9.75% | ||
ROE | -11.29% | ||
Debt/Equity | 0 |
18 analysts have analysed ROIV and the average price target is 20.04 USD. This implies a price increase of 24.96% is expected in the next year compared to the current price of 16.04.
For the next year, analysts expect an EPS growth of -477.03% and a revenue growth -75.92% for ROIV